Products & Technology
The VMT01 program is entering a Phase 1 imaging trial at the Mayo Clinic in Rochester, MN. This is expected to be followed closely by a Phase 1/2a therapy study for the treatment of metastatic melanoma based on the results of the imaging trial.
Melanoma is a cancer of the skin and the most aggressive form of skin cancer. While disease that is identified early (when confined to the outer layers of the skin) can be cured by surgery, melanoma that migrates to distant sites in the body (metastatic melanoma) is difficult to treat. Despite the introduction of new treatments for metastatic melanoma, according to the American Cancer Society, the 5-year survival is approximately 25%.
Viewpoint’s VMT01 program is intended to meet this unmet medical need using a theranostic approach in which a diagnostic imaging scan is used to identify metastatic melanoma patients who can benefit from the VMT01 therapeutic. Using information guided by the low-risk medical imaging scan, a treatment plan utilizing the VMT01 ligand is designed to deliver the power of alpha-particle radiation specifically to melanoma tumors, while minimizing risk to unaffected organs and tissues. This work has been funded by the National Cancer Institute of the National Institutes of Health for awards of nearly $6M toward the advancement of the VMT01 program to clinical introduction. VMT01 represents an entirely new way to treat metastatic melanoma that has been vetted as scientifically sound by rigorous peer review and has the potential to be transformative for melanoma patients.
Links to more information:
Cancer.org - Survival Rates for Melanoma Skin Cancer
Science Direct - Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges
ACS Journals - CA: A Cancer Journal for Clinicians
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enabling the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.